Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TALVEY® (talquetamab-tgvs)

Medical Information

+ Save link

TALVEY - Use With Vaccines

Last Updated: 07/25/2024

SUMMARY

Immune response to vaccines may be reduced when taking TALVEY.¹
The safety of immunization with live viral vaccines during or following TALVEY treatment has not been studied.¹
Vaccination with live virus vaccines is not recommended for at least 4 weeks prior to the start of treatment, during treatment, and at least 4 weeks after treatment.¹

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 08 July 2024.

References

Show

1	Data on File. Talquetamab. Janssen Research and Development, LLC. EDMS-RIM-620984; version 002; 2024.